Demographic and biologic characteristics of 84 elderly adults with newly diagnosed AML treated with T + E
| . | Arm A (n = 63) . | Arm B (n = 21) . | Total (n = 84) . |
|---|---|---|---|
| Sex, no. (%) | |||
| Male | 39 (63) | 14 (67) | 53 (63) |
| Female | 24 (38) | 7 (33) | 31 (37) |
| Median age, y (range) | 76 (70-90) | 78 (71-90) | 76 (70-90) |
| Biologic disease features, no. (%) | |||
| Secondary AML | 36 (57) | 10 (48) | 46 (55) |
| MDS/AML | 24 | 7 | 31 |
| t-AML | 12 | 3 | 12 |
| Prior therapy* | 10 (28) | 5 (50) | 15 (33) |
| Adverse cytogenetics† | 38 (60) | 14 (67) | 52 (62) |
| Single | 10 | 4 | 14 |
| Complex (> 3 lesions) | 19 | 7 | 26 |
| Other | 9 | 3 | 12 |
| No. with > 1 poor risk feature | 47 (75) | 15 (71) | 62 (74) |
| Host comorbidities, no. (%) | |||
| 1 comorbidity | 61 (97) | 19 (90) | 80 (95) |
| 3 comorbidities | 36 (57) | 13 (62) | 49 (58) |
| . | Arm A (n = 63) . | Arm B (n = 21) . | Total (n = 84) . |
|---|---|---|---|
| Sex, no. (%) | |||
| Male | 39 (63) | 14 (67) | 53 (63) |
| Female | 24 (38) | 7 (33) | 31 (37) |
| Median age, y (range) | 76 (70-90) | 78 (71-90) | 76 (70-90) |
| Biologic disease features, no. (%) | |||
| Secondary AML | 36 (57) | 10 (48) | 46 (55) |
| MDS/AML | 24 | 7 | 31 |
| t-AML | 12 | 3 | 12 |
| Prior therapy* | 10 (28) | 5 (50) | 15 (33) |
| Adverse cytogenetics† | 38 (60) | 14 (67) | 52 (62) |
| Single | 10 | 4 | 14 |
| Complex (> 3 lesions) | 19 | 7 | 26 |
| Other | 9 | 3 | 12 |
| No. with > 1 poor risk feature | 47 (75) | 15 (71) | 62 (74) |
| Host comorbidities, no. (%) | |||
| 1 comorbidity | 61 (97) | 19 (90) | 80 (95) |
| 3 comorbidities | 36 (57) | 13 (62) | 49 (58) |
t-AML indicates treatment-related AML.
Includes previous therapy for MDS and t-MDS with growth factors, demethylating agents, thalidomide, or lenalidomide individually or in combinations.
Adverse cytogenetics: −5/5q, −7/7q, abnormal 3/3q, abnormal 11q23, abnormal 17p, −20q, +13, t(6;9), t(9;22), complex (> 3 abnormalities).